Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
CH0325814116
Thu, 15.09.2022
Kuros Biosciences AG
Schlieren (Zurich), Switzerland, September 15, 2022 – Kuros Biosciences AG (SIX:KURN) a leader in next generation bone graft technologies, announced today the successful completion of a CHF 6.0 million capital increase through a private placement of 3,750,000 new shares of Kuros with a par value of CHF 0.10 each (the "New Shares" and the "Placement [ … ]
Tue, 09.08.2022
Kuros Biosciences AG
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules
Financial highlights
CHF 29.4 million cash & cash equivalents, trade and other receivables as of June 30, 2022
Product sales increased by 58% to CHF 5.7 million
Operational highlights
FDA cleared MagnetOs Granules for use in expanded spinal indications
FDA cleared M [ … ]
Tue, 09.08.2022
Kuros Biosciences AG
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules
Financial highlights
CHF 29.4 million cash & cash equivalents, trade and other receivables as of June 30, 2022
Product sales increased by 58% to CHF 5.7 million
Operational highlights
FDA cleared MagnetOs Granules for use in expanded spinal indications
FDA cleared M [ … ]
Wed, 08.06.2022
Kuros Biosciences AG
Schlieren (Zurich), Switzerland, June 8, 2022 – Kuros Biosciences (SIX:KURN) today announced that its Annual General Meeting approved all resolutions proposed by the Board of Directors.
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules
The Annual General Meeting approved the Annual Report, the Annual Financial Statements, and [ … ]
Wed, 27.04.2022
Kuros Biosciences AG
Medical devices Q1 2022 sales accelerate, rising 102% over Q1 2021
FDA cleared MagnetOs Granules for expanded indications in spine and MagnetOs Flex Matrix as bone void filler in posterolateral spine
Promising first-in-human data from Phase II trial of Fibrin-PTH (KUR-113) in tibial fractures
Milestone payment of $5 million to be received from [ … ]
Thu, 21.04.2022
Kuros Biosciences AG
Clearance as a bone void filler for use in the posterolateral spine
Third FDA clearance for MagnetOs in the last 7 months
Product provides opportunity to de-risk U.S. commercialization plans
Schlieren (Zurich), Switzerland, April 21, 2022 - Kuros Biosciences ('Kuros' or the 'Company'), a leader in next generation bone graft technologies, announc [ … ]
Wed, 16.03.2022
Kuros Biosciences AG
Financial highlights
CHF 30.7 million cash & cash equivalents, trade and other receivables at December 31, 2021
Product sales increased more than 100% to CHF 8.3 million
Received USD 6 million (CHF 5.5 million) milestone payments from Checkmate Pharmaceuticals
Received USD 7 million (CHF 6.4 million) up front with USD 166.5 million [ … ]
Tue, 26.10.2021
Kuros Biosciences AG
Ad hoc announcement pursuant to Article 53 of the SIX listing rules
MagnetOs U.S. YTD sales increase 119% in 2021 compared to 2020
Kuros expanding MagnetOs range to increase perioperative solutions for surgeons
Schlieren (Zurich), Switzerland, 26 October 2021 - Kuros Biosciences ('Kuros' or the 'Company'), a leader in next generation bone graft te [ … ]
Wed, 11.08.2021
Kuros Biosciences AG
Ad hoc announcement pursuant to Article 53 of the SIX listing rules
Financial Highlights
CHF 29.4 million cash & cash equivalents, trade and other receivables as of June 30, 2021
Received CHF 5.5 million milestone payments from Checkmate Pharmaceuticals
Acceleration of product sales to CHF 3.6 million, up from CHF 1.3 million in H1 2020
Net [ … ]
Thu, 15.07.2021
Kuros Biosciences AG
Ad hoc announcement pursuant to Article 53 of the SIX listing rules
Schlieren (Zurich), Switzerland, 15 July, 2021 - Kuros Biosciences AG ('Kuros' or the 'Company'), a leader in next generation bone graft technologies, announced today that it has entered into a royalty purchase agreement with XOMA Corporation (NASDAQ: XOMA) under which XOMA has pur [ … ]